Generate Biomedicines (NASDAQ:GENB) reported quarterly losses of $(1.07) per share which missed the analyst consensus estimate of $(0.54) by 98.15 percent. This is a 33.95 percent increase over losses of $(1.62) per share from the same period last year. The company reported quarterly sales of $7.224 million which beat the analyst consensus estimate of $5.938 million by 21.67 percent. This is a 18.08 percent decrease over sales of $8.818 million the same period last year.